Nimbus Thinks It Has “Non-First-Mover” Advantage In NASH
This article was originally published in The Pink Sheet Daily
Executive Summary
Working on an allosteric ACC inhibitor in NASH, Nimbus is not worried about being first to market but is willing to let others develop and prove out a pivotal development pathway in the indication, while it focuses on a unique mechanism of action.